Trial Profile
An Open-Label, Multi-Center, Add-On Study Of Pregabalin (LYRICA) In Subjects With Refractory Partial Seizures Who Have Completed Studies 1008-010, 1008-035, 1008-114 Or 1008-164.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors Pfizer
- 16 Dec 2011 Actual patient number is 21 according to ClinicalTrials.gov.
- 16 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 16 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.